Skip to main content
. 2022 Mar 7;8(1):20552173221085737. doi: 10.1177/20552173221085737

Table 1.

Patients’ demographics.

Demographics
Age at conception, mean (SD) 34.8 years (2.9)
Duration of disease, mean (SD ) 65.2 months (54.3)
Number of ocrelizumab infusions at conception, mean (SD ) 1.9 (0.9)
Number of previous DMTs, N (%) 0 4 (33.3%)
1–2 4 (33.3%)
3 or more 4 (33.3%)
Ocrelizumab exposure, N (%) Preconception 13 (92.9%)
First trimester 3 (21.4%)
Second/third trimester 0